Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189703 | 0.88 | HDAC3 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL21348198 | 0.82 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15590852 | 0.81 | HDAC3 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15233019 | 0.81 | HDAC1 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15590854 | 0.81 | HDAC3 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL14280518 | 0.79 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15290260 | 0.77 | HDAC3 (0.46) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL13590556 | 0.77 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL21328519 | 0.77 | HDAC3 (0.40) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL16147762 | 0.77 | HRH3 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109745983-A | A kind of preparation method and applications for the copper nano particles that graphene quantum dot is stable | 三峡大学 | 2019-05-14 | — | — | CN | claimed |
| EP-3380447-B1 | METHOD FOR SYNTHESIZING IODO- OR ASTATOARENES USING DIARYLIODONIUM SALTS | INST NAT SANTE RECH MED (FR) | 2025-09-03 | — | — | EP | disclosed |
| CN-112094259-B | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-109745983-B | Preparation method and application of copper nanoparticles with stable graphene quantum dots | 三峡大学 | 2021-10-19 | — | — | CN | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-112094259-A | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| US-10858306-B2 | Method for synthesizing iodo- or astatoarenes using diaryliodonium salts | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2020-12-08 | — | — | US | disclosed |
| CN-106458960-B | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200239404-A1 | METHOD FOR SYNTHESIZING IODO- OR ASTATOARENES USING DIARYLIODONIUM SALTS | NANTES UNIVERSITE (FR) | 2020-07-30 | — | — | US | disclosed |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434699-B2 | Iodine(III)-mediated radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2015134923-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134923-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252007-A1 | IODINE(III)-MEDIATED RADIOFLUORINATION | TPO, FLI1, SSTR3 | HDAC3 772/4885HDAC1 2832/4885HDAC2 3186/4885 |
| US-20200239404-A1 | METHOD FOR SYNTHESIZING IODO- OR ASTATOARENES USING DIARYLIODONIUM SALTS | SGMS2, SGMS1, PTDSS2 | HDAC3 1220/4885HDAC1 2180/4885HDAC2 1799/4885 |
| US-10858306-B2 | Method for synthesizing iodo- or astatoarenes using diaryliodonium salts | SGMS2, SGMS1, PTDSS2 | HDAC3 1220/4885HDAC1 2180/4885HDAC2 1799/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | HDAC3 2365/4885HDAC1 2099/4885HDAC2 2211/4885 |
| US-20160362375-A1 | Iodine(III)-Mediated Radiofluorination | TPO, FLI1, SSTR3 | HDAC3 772/4885HDAC1 2832/4885HDAC2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.